This inventor holds 3 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: Abbvie Inc.. Active years: 2016-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2021
Title: Brian P Enright: Innovator in Parkinson's Disease Treatment
Introduction
Brian P Enright is a notable inventor based in Gurnee, IL (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Parkinson's disease. With a total of 3 patents, his work focuses on innovative methods and compositions that aim to improve the quality of life for those affected by this condition.
Latest Patents
Enright's latest patents include groundbreaking methods for treating Parkinson's disease. One of his key disclosures involves carbidopa prodrugs and pharmaceutical combinations that comprise both carbidopa and L-dopa prodrugs. These methods are designed to effectively treat Parkinson's disease and its associated conditions by administering these prodrugs to affected subjects. His research emphasizes the importance of these compounds in enhancing therapeutic outcomes for patients.
Career Highlights
Brian P Enright is currently associated with AbbVie Inc., a leading global biopharmaceutical company. His work at AbbVie has allowed him to focus on developing innovative treatments that address critical health issues. His dedication to research and development has positioned him as a key figure in the pharmaceutical industry.
Collaborations
Enright collaborates with esteemed colleagues such as Ye Huang and Philip R Kym. These partnerships enhance the research efforts and contribute to the advancement of treatments for Parkinson's disease.
Conclusion
Brian P Enright's contributions to the field of pharmaceuticals, particularly in the treatment of Parkinson's disease, highlight his innovative spirit and commitment to improving patient care. His work continues to pave the way for new therapeutic options that can significantly impact the lives of those affected by this condition.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile